Helicore Biopharma Secures $65M Series A to Revolutionize Obesity Treatment Development

Helicore Biopharma, Inc., a clinical-stage biopharmaceutical company at the forefront of tackling obesity and related metabolic disorders, is thrilled to announce the successful close of a $65 million Series A financing round in January 2024. This significant capital infusion underscores the confidence that investors have in Helicore’s pioneering approach to therapeutic innovation. At the heart of the company’s strategy is its novel approach to targeting the glucose-dependent insulinotropic peptide (GIP) pathway. Helicore’s unique platform employs proprietary monoclonal antibodies that bind to the circulating GIP ligand, a breakthrough designed to enhance the efficacy, dosing flexibility, and overall tolerability of anti-obesity treatments. With obesity remaining a critical and growing public health concern, Helicore aims to fill an important unmet need by advancing next-generation therapies that offer superior treatment outcomes. The funds raised will be strategically directed toward accelerating clinical trials, expanding research and development initiatives, and scaling up manufacturing capabilities to support future product commercialization. In addition, this investment enables Helicore Biopharma to deepen its commitment to scientific excellence and innovation, ensuring that its novel portfolio continues to progress efficiently through the development pipeline. As the company moves forward with an enhanced focus on improving patient care, stakeholders can expect further milestones in optimizing therapeutic regimens that promise not only improved efficacy but also more convenient dosing schedules for end users. For more detailed information about their groundbreaking work and future developments, visit www.helicore.com.